Protagenic Therapeutics unwinds Phytanix Bio acquisition, pays $310k, settles litigation

Protagenic Therapeutics, Inc.new

Settlement and Unwind Agreement executed Feb 17, 2026; SEA dated May 15, 2025 terminated.
PTIX returns 100% of Phytanix Bio shares; receives back all PTIX common and preferred stock issued as consideration.
PTIX pays Phytanix Bio $300,000 at closing and $10,000 upon receipt of specified financial information.
Litigation styled Protagenic v. Alterola Biotech et al. dismissed with prejudice.
Mutual releases and indemnification provisions between parties; former Phytanix stockholders resign from PTIX positions.

item 1.01item 1.02item 2.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.